Silo Pharma, Inc. Operating Income Loss

• Silo Pharma, Inc. showed an increase of +9.0% in Operating Income Loss from 2024 to 2025.
• This data is from Silo Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2017 to 2025), Silo Pharma, Inc.'s Operating Income Loss has declined by 772.1%.
• Historical annual values: Fiscal year 2025: -$4.28 million | Fiscal year 2024: -$4.71 million | Fiscal year 2023: -$3.86 million | Fiscal year 2022: -$3.63 million | Fiscal year 2021: -$2.74 million | Fiscal year 2020: -$2.20 million | Fiscal year 2019: -$930.4 thousand | Fiscal year 2018: -$594.2 thousand | Fiscal year 2017: -$490.9 thousand.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026